JPRN-UMIN000028761已完成未知
The efficacy of a human interleukin 12/23 monoclonal antibody and investigation of expression of IL12/23p40 in Crohn disease anorectal lesion. - The efficacy of a human interleukin 12/23 monoclonal antibody and investigation of expression of IL12/23p40 in Crohn disease anorectal lesion.
适应症
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 入组人数
- 100
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Observational
入排标准
- 年龄范围
- 10years-old 至 ot applicable（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •Age under 10 yrs. Patients without consent.
研究者
相似试验
招募中
2 期
Anti-malaria Monoclonal Antibody for Malaria Prevention in Kenyan childreMalariaPACTR202205899641128ational Institutes of Health396
进行中（未招募）
1 期
Efficacité des immunoglobulines humaines normales (IGHN) dans les chocs toxiques (staphylococciques et streptococciques) : étude de faisabilité pédiatrique.MedDRA version: 18.0Level: PTClassification code 10044248Term: Toxic shock syndromeSystem Organ Class: 10021881 - Infections and infestationstoxic shock syndromeEUCTR2013-005509-29-FRHospices Civils de Lyon20
进行中（未招募）
1 期
Treatment with Anakinra for patients with anaplastic thyroid cancerAnaplastic Thyroid CarcinomaEUCTR2017-003028-59-NLRadboud University Medical Centre10
已完成
不适用
Treatment with Recombinant human Interleukin 1 receptor antagonist (Anakinra) in patients with Anaplastic Thyroid Cancer: a proof of concept studyNL-OMON46644Radboud Universitair Medisch Centrum10
尚未招募
不适用
Treatment with recombinant human Interleukin 1 receptor antagonist (Anakinra) in patients with anaplastic thyroid cancer: a proof of concept studyNL-OMON22269Radboud UMC Nijmegen, The Netherlands10